Mr. Aldrich is a Co-Founder of OvaScience and is Chairman of the company’s Board of Directors. Mr. Aldrich is also a Founder and Partner of Longwood Fund, which founds and invests in biotechnology companies. Mr. Aldrich has co-founded and helped to build several successful biotech companies including Sirtris Pharmaceuticals (acquired by GlaxoSmithKline), Concert Pharmaceuticals, Alnara Pharmaceuticals (acquired by Eli Lilly in 2010) and Verastem. Prior to co-founding Longwood, he was General Partner of RA Capital, a biotechnology investment fund he founded in 2001. Mr. Aldrich was a founding employee of Vertex Pharmaceuticals, where he held the position of Senior Vice President and Chief Business Officer and managed all commercial and operating functions from 1989 to 2001. Prior to joining Vertex, Mr. Aldrich held several management positions at Biogen, Inc. Mr. Aldrich serves on the Board of the Massachusetts Eye & Ear Infirmary.
Mr. Aldrich received his undergraduate degree from Boston College, and an M.B.A. from the Amos Tuck School at Dartmouth College.
Jeffrey D. Capello is the Executive Vice President and Chief Financial Officer of Boston Scientific, a position he has held since March 2010. He is directly responsible for the worldwide management of Boston Scientific's Finance Information Systems, Business Development and Corporate Strategy functions. Mr. Capello joined Boston Scientific in June 2008 and served as Senior Vice President and Chief Accounting Officer until March 2010. Prior to joining Boston Scientific, he was the Senior Vice President and Chief Financial Officer with responsibilities for Business Development at PerkinElmer, Inc. from 2006 to 2008. Prior to that, he served as PerkinElmer's Vice President of Finance, Corporate Controller and Treasurer from 2002 to 2006 and as Vice President, Finance, Corporate Controller, Chief Accounting Officer and Treasurer from 2001 to 2005. From 1991 to June 2001, he held various positions including that of partner from 1997 to 2001, at PricewaterhouseCoopers LLP, a public accounting firm, initially in the United States and later in the Netherlands. Mr. Capello was a member of the board of directors of Sirtris Pharmaceuticals, Inc. (acquired by GlaxoSmithKline) and served on its Audit Committee as both a member and its chair.
Mr. Capello holds a B.S. degree in business administration from the University of Vermont and an M.B.A. degree from the Harvard Business School. Mr. Capello is also a certified public accountant.
Dr. Dipp is the founding Chief Executive Officer of OvaScience and serves on the Board of Directors. Dr. Dipp is also a Founder and Partner of Longwood Fund, which founds and invests in healthcare companies such as Alnara (acquired by Eli Lilly) and Verastem. Previously, Dr. Dipp was the Senior Vice President and Head of the CEEDD at GlaxoSmithKline. Prior, she was Vice President of Corporate Development at Sirtris, where she led the successful acquisition of Sirtris by GSK for $720 million. Before joining Sirtris as a founding employee, she worked in healthcare private equity at The Wellcome Trust, London. Dr. Dipp serves on the Biotechnology Industry Organization’s (BIO) Emerging Companies Governing Board, the Beth Israel Deaconess Medical Center Board of Trustees, the Boston Symphony Orchestra Board of Overseers, and the MassBio Advisory Board.
Dr. Dipp holds an M.D. and a Ph.D. from the University of Oxford.
Ms. Fisher serves on the Board of Directors of OvaScience and brings more than 25 years of experience in the pharmaceutical and biotechnology industries. Ms. Fisher currently serves as Chief Executive Officer and Director at Colorescience, a former division of SkinMedica, Inc., where she served as Chief Executive Officer from 2008 until 2012, when she led the successful sale of the company to Allergan, Inc. for $375 million. Prior to joining SkinMedica, Ms. Fisher was the Chief Operating Officer of Acorda Therapeutics, where she was responsible for the execution of the company’s restructuring, initial public offering and a $50 million acquisition that transitioned Acorda from a developmental platform to a commercial stage operation. Ms. Fisher has served as a Pharmaceutical Consultant for companies such as Acorda Therapeutics and Roche Diagnostics and specialized in commercialization strategy, resource and outsource planning, pricing strategy and tactics, distribution planning, managed care contracting and forecasting. Previously, she held the role of Vice President, Strategic Healthcare and Commercial Operations at Cephalon, Inc., and Manager, Communications at Immunex. She currently serves as a Board Member of the Neuroscience Nursing Foundation and is a Member of the Women’s Dermatological Society and the Dermatology Foundation Leader’s Society. Additionally, Ms. Fisher co-founded Ann Olsen Endowment, a cancer patient advocacy group, in 1987.
Mr. Kraus serves on the Board of Directors of OvaScience and is a partner of Bessemer Venture Partners (BVP) in the company’s Cambridge, Mass. Office. He has worked with BVP since 2004 and focuses on the healthcare sector. Mr. Kraus has been actively involved in BVP’s investments in Sirtris Pharmaceuticals (acquired by GlaxoSmithKline); Affymax; AVEO Pharmaceuticals; Alnara, acquired by Eli Lilly; Transave; and Restore Medical, acquired by Medtronic. He currently sits on the boards of Verastem, Stromedix and On-Q-ity and is actively involved in BVP's investments in Acceleron, Proteon, Oxagen and Cerulean. Prior to joining Bessemer, Mr. Kraus was a Director at the Ironwood Equity Fund, a growth-stage, private-equity firm, and a management consultant at Bain & Co. In 2002, he served as speechwriter and Operations Director for the Democratic nominee for Governor of Massachusetts.
Mr. Kraus graduated summa cum laude with a B.A. from Yale University and earned his M.B.A. from Harvard, where he was a Baker Scholar. He serves on the boards of the New England Venture Capital Association (NEVCA) and Interise, a non-profit focused on small-business job creation and entrepreneurship.
Thomas Malley has served on our board of directors since October 2012. He has been President of Mossrock Capital, a private investment firm in Denver, Colorado, since 2007. From 1991 until 2007 Mr. Malley worked at Janus Mutual Funds. From 1999–2007, he started and served as the portfolio manager of the Janus Global Life Sciences Fund, as well as being Vice President in charge of the Janus Healthcare team. From 1991-1998 he served as an equity analyst for Janus covering healthcare and biotechnology, telecommunications, gaming and lodging, and housing stocks. Mr. Malley serves on the board of directors of Synageva Biopharma and Puma Biotechnology, both of which are publicly traded biotechnology firms. In the past, he served on the board of Cougar Biotechnology from 2007–2009, prior to its acquisition by Johnson and Johnson.
Mr. Malley earned his B.S. degree in Biology from Stanford University in 1991.
Mr. Stock serves on the Board of Directors of OvaScience and is the Chief Executive Officer of the Grünenthal Group, an international research-based pharmaceutical company headquartered in Germany. Prior to joining Grünenthal in 2009, he was Chairman and Managing Director of the German DePuy Group, the Orthopaedics Division of Johnson & Johnson. Previously, he held various positions of increasing responsibilities in local and global functions and corporate divisions of the Roche Group until 2005, when he was appointed Senior Vice President of the Global Near Patient Testing business based in Graz, Austria. Mr. Stock is a Board Member at the European Federation of Pharmaceutical Industries and Associations (efpia) and immatics biotechnologies GmbH. He also previously served as Vice-Chairman of the Supervisory Board of PAION AG, was Board Observer of ConforMIS, Inc. and represented Johnson & Johnson on the Board of BVMed, the German Medical Technology Industry Association.
Fertility expert, Dr. Tilly, is a Co-Founder of OvaScience and Co-Chairman of the company’s Scientific Advisory Board. Dr. Tilly joined the faculty of Johns Hopkins University as an Assistant Professor in 1993, and moved to Massachusetts General Hospital (MGH) in 1995 as Associate Professor of Obstetrics, Gynecology and Reproductive Biology at Harvard Medical School (HMS) to direct the newly-created Vincent Center for Reproductive Biology at MGH. He was promoted to Professor of Obstetrics, Gynecology and Reproductive Biology at HMS in 2009. Dr. Tilly's primary area of research is on the development of methods for preserving or reviving fertility and prolonging or restoring ovarian function in young girls and women. These studies have greatly expanded our understanding of such basic processes as menopause, infertility resulting from cancer treatments, and premature ovarian failure caused by exposure to toxic chemicals in the environment. In addition to reporting the first animal model that fails to undergo its equivalent of menopause with age, Dr. Tilly and his associates developed the first therapy that protects ovaries from the ravages of cytotoxic therapies. Recently, Dr. Tilly has taken a much different approach to new methods of fertility preservation and extension of ovarian function based on his discovery of egg precursor cells in the ovaries of adult mice that are capable of generating new eggs. Following publication of this ground-breaking study in Nature in 2004, Dr. Tilly re-focused his entire lab on characterization of oocyte-producing cells to demonstrate that ovarian failure can be reversed through egg precursor cell-based technologies. In addition to this line of work, Dr. Tilly is an authority on how dietary caloric restriction (CR) and CR mimetics can be used to remarkably offset the negative impact of aging on ovarian function and egg quality.
Dr. Tilly obtained his Ph.D. in 1990, and then completed postdoctoral training at the University of California-San Diego School of Medicine and Stanford University Medical Center. Dr. Tilly is a member of the National Scientific Advisory Committee of the American Federation for Aging Research and is the recipient of a 10-year MERIT Award from the National Institute on Aging of the National Institutes of Health. His work has been published in 113 original research articles, 20 reviews, 14 editorials, 19 book chapters and two edited books. He is the recipient of three issued patents, including one for his discovery of oocyte-producing cells, and has three other patent applications currently under examination.
Dr. Westphal is a Partner of Longwood Fund, which founds and invests in medical companies, and is Chairman and CEO of Verastem. He was founder and CEO of Sirtris Pharmaceuticals (acquired by GlaxoSmithKline), which he took public and led as Chief Executive Officer until 2010. Dr. Westphal cofounded Alnara Pharmaceuticals (acquired by Eli Lilly in 2010), and was co-founder/CEO of Alnylam Pharmaceuticals and Momenta Pharmaceuticals. Dr. Westphal serves on the board of directors of Ovascience (which he cofounded), and serves on the Board of Fellows of Harvard Medical School, and the Board of Overseers of the Boston Symphony Orchestra.
Dr. Westphal earned his M.D. from Harvard Medical School and Ph.D. in genetics from Harvard University and he graduated with a B.A. summa cum laude and Phi Beta Kappa from Columbia University.